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Abstract 
The aim of the present study was to ascertain the cumulative incidence of first hormone replacement therapy (HRT) 
and the factors that predict its prescription. In a general population 1689 women were followed for 9 months in order 
to trace first HRT prescriptions. Determinants (well-being, attitude towards menopause, menopausal status and 
another 9 variables) were measured by means of a questionnaire. Data analyses were performed for all women and 
for women with or without typical climacteric complaints. The cumulative 9 month incidence of HRT was 6.2%. For 
women without typical complaints a lower level of well-being (odds ratio 5.5; 95% CI 1.9-15.5) and the former use 
of the contraceptive pill (odds ratio 4.6; 95% CI 1.0-20.5) were independently associated with HRT prescription. For 
women with typical complaints a positive attitude towards ‘menopause should be treated’ (odds ratio 3.8; 95% CI 
1.8-8.0) was a determinant of HRT prescription. The cumulative incidence of HRT prescription is high, but from 
additional data it is apparent that within a period of 1 year and 9 months the majority of women stop taking HRT. 
For women without typical complaints, physicians prescribe HRT five times more often to those with a lower level 
of well-being. For women with typical complaints the physician’s prescription is primarily related to the woman’s atti- 
tude towards (medical) treatment of the menopause. 
Keywords: Determinants; HRT; Well-being; Attitude towards menopause; Typical complaints; Climacteric 
1. Introduction 
Hormone replacement therapy has been avail- 
able for about 40 years. The first placebo controll- 
ed efficacy study was reported in 1950 [l]. Since 
* Corresponding author. 
then, many other studies have argued the benefits 
of HRT. They have provided evidence that HRT 
is profitable for women in the climacteric years 
with vasomotor complaints, vaginal dryness and 
disturbances in menstruation pattern (the so-called 
typical complaints). Furthermore, HRT is prob- 
ably useful in the prevention of postmenopausal 
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bone loss [2-41 and death from coronary heart 
disease [5-71. Nevertheless, several authors report 
a low prevalence of HRT use [8,91. 
Several factors that influence the decision to use 
HRT have been reported in the literature. The 
regular withdrawal bleeding as a result of the cyc- 
lic oestrogen/progestagen therapy is often ex- 
perienced as unacceptable [lO,l 11. Also, fear of 
cancer seems to be an important reason to refrain 
from HRT [12]. In contrast, women who are in- 
terested in health promotion and disease preven- 
tion measures are more willing to take estrogens 
[ 13). Furthermore, a higher rate of medical con- 
sultations, a belief in the efficacy of medical treat- 
ment (especially hormonal treatment), experience 
of hot flushes, women’s overall experience of 
menopause, parity, education and smoking behav- 
iour may influence the use of HRT [ 14- 151. 
Next to these factors which are related to the 
women, doctor-related factors may be equally im- 
portant, e.g. the judgment of the physicians con- 
cerning HRT leads to considerable differences in 
prescribing behaviour and a clear inter-doctor 
variability has been documented [ 16,171. 
The aim of this study was to estimate the cumu- 
lative incidence of first HRT prescription and the 
influence of the woman’s well-being, attitude 
towards menopause, menopausal status and other 
variables on first HRT prescription in a popula- 
tion at large during a 9 month follow-up period. 
For women as well as their doctors the so-called 
typical complaints are probably the major indica- 
tion for HRT [8,18,19]. Therefore, the incidence 
and determinants of HRT were studied among 
women with and without these complaints. 
2. Subjects and methods 
2.1. Recruitment 
This study is part of a larger study aimed at 
assessing the relationships between climacteric, 
well-being, women’s attitude towards menopause 
and medical attention. The methods applied to 
measure well-being and attitude towards meno- 
pause have been reported in detail elsewhere 
[20,21]. In short, from the municipal authorities of 
Krimpen aan den Ijssel, a commuter suburb of 
Rotterdam with approximately 28 000 inhabitants, 
names and addresses of all 2729 women aged be- 
tween 45-60 years were obtained. In May 1990 
they were sent a questionnaire; 1947 women 
responded (response 71.3%). A random sample 
(N = 55) was taken of the non-respondents in 
order to evaluate the representativity of the re- 
spondent group. They were approached by tele- 
phone and 52 participated (response 95%). The 
comparison between respondents and non- 
respondents revealed no statistically significant 
differences in age, menopausal status, hysterecto- 
my, estrogen therapy, level of education, work 
outside the home or medical attention. 
To measure the cumulative incidence of first 
HRT prescriptions, assistance was given by the 
two pharmacies in Krimpen aan den Ijssel. Both 
pharmacies are computerized. Of the women who 
returned the questionnaire, the 220 women (preva- 
lence 11.5%) who had used estrogen therapy 
within 6 months preceding answering the question- 
naire and the 7 women who used progestagens 
without estrogens were excluded. A further 31 
women could not be traced in the pharmacies’ 
database. The remaining 1689 women were 
registered at the pharmacies, included in the study 
and followed for a period of 9 months. The follow- 
up period lasted from July 1st 1990 until April 1st 
1991. 
The study received approval from the Medical 
Ethical Committee of the Erasmus University and 
Academic Hospital Dijkzigt in Rotterdam. 
2.2. Measurements 
General well-being was measured by two 
validated inventories: the ‘Inventory of Subjective 
Health’ (ISH) and the ‘Sickness Impact Profile’ 
(SIP). The ISH has proven to be a sensitive instru- 
ment to detect health problems [22-241. The ISH 
includes 49 items, concerning the experience in the 
past 2 weeks, for example; pains in the chest, 
trembling hands, headache, sneezing and loss of 
appetite. On every item the respondent is asked 
whether she has experienced this during the last 2 
weeks. All items must be answered with either ‘yes’ 
or ‘no’. The maximum score is 49. The SIP was 
developed in the United States as a behaviourally 
based measure of the impact of sickness [25]. In 
this study, the Dutch validated version has been 
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Table I 
Cumulative incidence within 9 months of first hormone replacement therapy among 1689 women aged 45-60 years (%) 
All women Pa Without P With P 
typical typical 
complaints complaints 
Total (n) 6.2 (104) 4.4 (37) 8.0 (67) 
Measures of well-beingb 
ISH (1251) 
below median 
above median 
SIP - social interaction (1335) 
below median 
above median 
SIP - emotions, feelings and sensations (1509) 
below median 
above median 
SIP - intellectual functioning (1454) 
below median 
above median 
0.001 
4.4 
9.0 
5.5 
6.8 
5.1 
8.8 
5.9 
6.7 
0.316 
0.005 
0.518 
0.002 
2.9 
8.6 
0.701 
3.9 
4.5 
0.069 
3.9 
7.0 
0.668 
3.9 
4.5 
6.7 
9.2 
7.7 
8.5 
6.5 
9.9 
8.2 
8.2 
Attitude measurements 
Menopause is disadvantageous (1294) 
more positive 
more negative 
Menopause is advantageous (1299) 
more positive 
more negative 
Menopause should be treated (1424) 
more positive 
more negative 
0.217 
6.9 
5.3 
5.1 
7.0 
8.5 
3.6 
0.168 
0.000 
5.2 
3.5 
3.6 
4.7 
4.7 
2.8 
0.308 
0.510 
0.182 
8.2 
7.3 
6.5 
9.1 
12.1 
4.4 
Menopausal status 
Menopausal status according to last 
menstrual bleeding (I 332) 
premenopausal 
perimenopausal 
postmenopausal 
Menopausal status according to the women 
themselves (1594) 
premenopausal 
perimenopausal 
postmenopausal 
0.401 0.071 
7.0 6.1 
7.3 6.9 
5.5 3.0 
9.3 
7.7 
1.6 
0.027 
5.0 
5.5 
2.1 
0.128 0.065 
7.0 
7.1 
3.3 
14.8 
8.0 
5.2 
Other variables 
Age-group, years (1641) 
45-50 
51-55 
56-60 
Education (I 65 I) 
low 
middle 
high 
9.2 
5.0 
3.5 
0.004 
0.910 
II.7 
6.5 
5.3 
3.5 
7.0 
6.0 
O.O@O 
7.1 
3.1 
1.8 
0.089 
3.9 
4.6 
5.0 
3.0 
9.3 
7.2 
0.260 
0.700 
0.082 
0.974 
0.674 
0.221 
0.000 
0.877 
0.014 
0.055 
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Table 1 
Cumulative incidence within 9 months of first hormone replacement therapy among 1689 women aged 45-60 years (u/o) 
All women P” Without P With P 
typical typical 
complaints complaints 
Body mass index, Kg/m* (1585) 
below median 
above median 
Smoking behaviour ( 1619) 
never 
I-1 S/day 
> 1 S/day 
Contraceptive pill (1643) 
never used 
formerly used 
Parity (1689) 
no children 
one child 
two children 
three children 
2 four children 
Hysterectomy (1659) 
no 
yes, unilateral oophorectomy 
yes, bilateral oophorectomy 
Medical attention last 2 weeks (1654) 
no 
yes 
General practice (1641) 
A 
B 
0.681 0.751 0.452 
5.9 4.8 7.0 
6.4 4.3 8.5 
0.004 0.092 0.039 
5.8 4.2 7.5 
4.4 1.6 7.0 
12.6 8.5 15.8 
0.000 0.037 0.002 
3.2 2.6 4.0 
8.0 5.7 10.2 
0.714 0.267 0.867 
5.0 1.8 7.8 
7.5 5.4 9.2 
6.2 3.6 8.7 
6.8 7.0 6.6 
4.7 3.2 6.7 
0.008 0.109 0.05 I 
5.5 4.0 6.8 
11.3 9.3 12.9 
9.3 4.3 15.0 
0.932 0.850 0.725 
6.3 4.4 8.3 
6.4 4.7 7.7 
0.036 0.088 0.239 
3.3 1.1 5.4 
3.5 2.1 4.8 
8.1 6.1 9.8 
6.5 4.0 9.7 
6.7 7. I 6.3 
“P-value based on the x-test. 
bISH, Inventory of Subjective Health; SIP, Sickness Impact Profile. 
used [26]. Both SIP overall scores and SIP cate- 
gory scores can discriminate between sub-samples 
of respondents. We have chosen three category 
scores which measure psycho-social impact on 
well-being: emotions, feelings and sensations (9 
items), social interaction (18 items) and intellectual 
functioning (10 items). All items are rated on a 
scaling factor. This scaling permits the calculation 
of three SIP percent category scores. A percentage 
of 100 means maximal impairment on the cor- 
responding category score. 
Three attitude clusters towards menopause were 
distinguished: two clusters encompass items reflec- 
ting the idea that ‘menopause is advantageous’ and 
‘menopause is disadvantageous’ and one cluster 
encompasses items reflecting the idea that ‘meno- 
pause should be treated (medically)’ [21]. The 
women were asked to rate their opinion on all 
items on a scale ranging from 1 (totally agree) to 
5 (totally disagree). Mean scores per cluster were 
computed. 
To ascertain menopausal status according to 
last menstrual bleeding, women were classified 
into pre-, peri- and postmenopausal according to 
menstrual history. Premenopausal women were 
women having a regular menstruation pattern in 
the preceding 12 months. Women were considered 
perimenopausal when irregular cycles or amenor- 
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rhoa had developed in the 12 months prior to the 
questionnaire. Women were classified as post- 
menopausal if last menstrual bleeding occurred at 
least 12 months ago. Women who had undergone 
hysterectomy were categorized as a separate 
group. 
The women were also asked to rate their 
climacteric phase themselves by choosing one of 
the following live categories: ‘I have not reached 
the menopause’ (classified as premenopausal), 
‘I have just reached the menopause’, ‘I am in the 
middle of the menopause’, ‘I have reached the end 
of the menopause’ (all three categories classified as 
perimenopausal), ‘I reached the menopause long 
ago’(classilied as postmenopausal). 
The methods used to measure the other poten- 
tial determinants of the initial HRT such as body 
mass index, smoking behaviour, parity, age, gener- 
al practice are shown in Table 1. 
Women were categorized as having typical 
(climacteric) complaints when they reported one 
or more of the following symptoms on the ques- 
tionnaire: hot flushes, severe sweating, vaginal 
dryness or menstruation disturbances. The pre- 
sence of severe sweating and vaginal dryness were 
assessed by using both a closed and an open ques- 
tion, whereas the presence of hot flushes and men- 
struation disturbances were assessed using an open 
question only. The closed questions were incor- 
porated in a symptom checklist, where the women 
could encircle either yes or no when they had 
regularly experienced a symptom during the last 
two weeks. In the open question the women could 
indicate any symptom they experienced during the 
last 4 weeks. 
2.3. Analysis 
The cumulative incidence of first HRT prescrip- 
tions during 9 months was computed. Linear vari- 
ables were dichotomized around the median. The 
association between possible determinants and 
first HRT prescriptions was studied by means of 
the x2-test. Determinants that were associated 
with first HRT prescription on a P < 0.10 level 
were then included in a logistic regression analysis 
to ascertain the relative contributions. For all or- 
dinal and nominal variables dummy variables were 
constructed to detect non-linear effects. The back- 
ward stepwise procedure was used retaining only 
variables that contributed on a P < 0.10 level to 
the prediction of first HRT prescriptions. 
As the relationships between the determinants 
and first HRT prescriptions may be modified by 
the presence of typical (climacteric) complaints, 
subgroup analyses were performed for the women 
without and women with typical complaints. 
3. Results 
The 9 month cumulative incidence of first HRT 
prescriptions was 6.2% (104 women). This equals 
a 1 year cumulative incidence of 8.2%. The inci- 
dence of first HRT prescriptions among women 
without typical complaints at baseline was 4.4%, 
whereas the incidence for women with typical 
complaints was 8.0%. 
3.1. Determinants offirst HRTprescriptions for all 
women 
Table 1 shows the relationship between first 
HRT prescriptions and possible determinants. 
Only statistically significant associations are 
reported below. Two measures of well-being 
predicted first HRT prescriptions: women below 
the median of the ISH - i.e. the half of women 
that feel relatively well - had an incidence of 4.4% 
whereas the women above the median of the ISH 
had an incidence of 9.0%. For the SIP - emo- 
tions, feelings and sensations, these figures were 
5.1% and 8.8%, respectively. From the attitude 
measurements, the cluster ‘menopause should be 
treated (medically)’ was related to HRT prescrip- 
tion. Women who thought more positively had an 
incidence of 8.5%, whereas the other women had 
an incidence of 3.6%. Only the menopausal status 
according to the women themselves was associated 
with first HRT. Of the premenopausal women 
7.0%, of the perimenopausal women 7.1% and of 
the postmenopausal women 3.3% started using 
HRT within the 9 months. 
Furthermore, women who were younger, 
women who smoked more than 15 cigarettes per 
day, women who formerly used the contraceptive 
pill and women who were hysterectomized were 
more often prescribed HRT. Women who were 
enlisted in general practice C had the highest inci- 
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Table 2 
Significant determinants from the multivariate logistic regression analysis of first hormone replacement therapy prescription among 
1689 women aged 45-60 years 
Variable contained in the 
regression model 
All women Women without 
typical complaints 
Women with 
typical complaints 
Odds ratio 95% c1a Odds ratio 95% CI Odds ratio 95% CI 
Variance accounted for by the 
variables 
Typical complaints 
not present 
present 
ISHb 
below median 
above median 
Menopause should be treated 
more negatively 
more positively 
Smoking behaviour 
never 
1 - I5 cigarettes 
> 15 cigarettes 
Contraceptive pill 
never used 
ever used 
3.8% 
1.0 
1.7 
1.0 
2.0 
1.0 
2.7 
1.0 
1.0 
2.2 
1.0 
2.3 
4.0% 2.8% 
- 
(0.9; 3.0) 
- 
1.0 
(1.1; 3.6) 5.5 (1.9; 15.5) 
- 
(1.5; 4.9) 
- 
1.0 
3.8 (1.8; 8.0) 
- 
(0.4; 2.2) 
(1.1; 4.6) 
- 
(1.1; 4.6) ::: (1.0; 20.5) 
‘95% CI, 95% confidence interval. 
bISH, Inventory of Subjective Health. 
dence of first HRT use (8.10/o), while women in 
general practice A had the lowest 9 month 
prescription rate (3.3%). 
The results of the multivariate logistic regression 
analysis are shown in Table 2. Within the 9 months 
of the study, women with typical complaints were 
prescribed HRT 1.7 times (95% CI 0.9; 3.0) more 
often than women without these complaints. The 
likelihood of HRT prescription for women above 
the median of the ISH was 2.0 (95% CI 1.1; 3.6) 
times higher than for women below the median. 
For the women who thought more positively 
about the attitude cluster ‘menopause should be 
treated’ the odds ratio equalled 2.7 (95% CI 1.5; 
4.9) compared to the women who thought more 
negatively. Women who smoked more than 15 
cigarettes a day had an odds ratio of 2.2 (95% CI 
1.1; 4.6) compared to women who had never 
smoked. Former use of the contraceptive pill 
resulted in a 2.3 (95% CI 1.1; 4.6) times higher 
prescription rate of HRT within the 9 months 
compared to women who never used the pill. 
3.2. Determinants offirst HRTfor women with and 
without typical complaints 
In the multivariate analyses (Table 2) all rela- 
tionships between determinants and HRT 
prescription appeared to be modified by the 
presence of typical complaints. For women with- 
out typical complaints the ISH and the former use 
of the contraceptive pill were determinants of ini- 
tial HRT prescription. Women above the median 
of the ISH had a 5.5 (95% CI 1.9; 15.5) higher rate 
of HRT than women below the median, while for 
former users of the contraceptive pill the odds 
ratio was 4.6 (95% CI 1.0; 20.5). 
For the women with typical complaints the atti- 
tude cluster ‘menopause should be treated’ was 
related to HRT prescription. Women who thought 
more positively about treatment had an odds ratio 
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of 3.8 (95% CI 1.8; 8.0) compared to women who 
thought more negatively. 
4. Discussion 
In this follow-up study of 1689 women aged 
45-60 years in an open population, the 9 month 
cumulative incidence of first hormonal replace- 
ment therapy prescriptions was 6.2%. When the in- 
dependent effects of several determinants were 
studied by means of a logistic regression analysis 
this incidence appeared to be higher for women (i) 
with typical complaints, (ii) with a lower level of 
well-being as measured by the ISH, (iii) with a 
more positive attitude towards ‘the menopause 
should be treated’, (iv) smoking more than 15 ciga- 
rettes a day and (v) who formerly used the con- 
traceptive pill. 
In this 9 month study a cumulative incidence of 
6.2% of first HRT was established, whereas the 
prevalence of HRT use at baseline was 11.5%. This 
implies that either the prevalence of HRT is rapid- 
ly increasing or that many women stop taking 
HRT. We were able to verify these options at the 
two pharmacies where the women were still 
registered. The pharmacies reported that one year 
and 9 months after the questionnaire 68 of the 103 
(66%) women were no longer prescribed HRT (one 
woman moved). Therefore, the problem of a low 
prevalence of HRT as stated by several studies 
[8,9,15] might be attributed to the problem of con- 
tinuating rather than starting HRT. 
Several determinants of HRT prescription that 
have been found in our study are in line with pre- 
vious findings. An association between general 
well-being and HRT has not been reported as a 
determinant of HRT in other studies. However, 
these studies were cross-sectional and therefore the 
level of well-being may already have been influenc- 
ed by HRT [14,15]. The relationship between atti- 
tude towards treatment and HRT has been found 
before [27]. Apparently, the belief in the efficacy 
of medical treatment of the menopause is at least 
as important as the presence of typical complaints. 
The relationship between smoking behaviour and 
HRT was ascertained in one study [28], but absent 
in another study [ 151. Perhaps women who smoke 
may therefore experience typical complaints more 
intensely. In several earlier studies, the former use 
of the contraceptive pill was a determinant of 
HRT use [ 151. Probably, once a woman has decid- 
ed to use hormones with a contraceptive purpose, 
she has less fear of cancer and other adverse 
effects. 
In our study, hysterectomy was, in contrast to 
other studies [15,29], a determinant in the 
univariate analysis only. Once well-being, smoking 
behaviour and/or former use of the pill were taken 
into account by means of the logistic regression 
analysis, the prediction of HRT prescription did 
not depend on hysterectomy. The same was found 
for the SIP emotions, feelings and sensations, the 
menopausal status according to the woman, age 
and general practice. 
The cumulative incidence for women with 
typical (climacteric) complaints was 8.0% versus 
4.4% for women without typical complaints. 
Hence, for the majority of the women a therapeu- 
tic indication existed. For women without and 
with typical complaints it appears that the predic- 
tion of HRT use is determined by different factors, 
i.e. a lower level of well-being and the former use 
of the contraceptive pill for women without these 
complaints and a positive attitude towards ‘meno- 
pause should be treated’ for women with these 
complaints. 
It is remarkable that a lower level of well-being 
as measured by the ISH determined HRT prescrip- 
tion (odds ratio = 5.5) for women without typical 
complaints. As yet, no clear views exist about the 
beneficial effect of HRT on well-being in the ab- 
sence of typical symptoms. From this we may ten- 
tatively conclude that a low level of well-being as 
measured by the ISH may influence the woman 
and/or her physician in the process leading to 
HRT prescription. In a study of Hunt a con- 
siderable influence of patient’s demand on HRT 
prescription was apparent (21% of all prescrip- 
tions) [ 191. This conclusion is also supported by 
the divergence in HRT prescription rates between 
the general practices, especially for women 
without typical complaints. Ferguson also 
observed differences between physicians in HRT 
prescription [27]. When typical complaints are 
present, the prescription of HRT mainly depends 
on the woman’s attitude towards ‘menopause 
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should be treated’ and not on her experienced level 
of well-being. 
To our knowledge this is the first study to assess 
the cumulative incidence of HRT and its deter- 
minants in an unselected population. By gathering 
the data from the pharmacists, neither the 
women’s nor the doctor’s attention was drawn to 
HRT prescription. The information about HRT 
provided in the last part of the questionnaire might 
have influenced the incidence of HRT in the first 
few months after the filling out of the question- 
naire. However, we did not find such an increase 
in the prescription. Another limitation of this 
study is the possibility of a change in typical com- 
plaints during the 9 month follow-up. Women 
were categorized as women with or without typical 
complaints according to the presence of these 
symptoms at the time of the questionnaire. Subse- 
quent changes in the experience of these com- 
plaints, which were not measured, may have been 
of influence on the prescription of HRT. Most 
likely this resulted in an under-estimation of the 
relationships reported in the separate analyses. 
Another limitation is the fact that we measured de- 
livery of HRT prescriptions and not the actual use. 
Moreover, some women might have incidentally 
filled HRT prescriptions in other pharmacies than 
the two present in Krimpen aan den IJssel. As 
there is a considerable distance to other phar- 
macies and only 3 1 out of 1947 women could not 
be traced at either pharmacy this will only have 
happened in few cases. Nevertheless a slight under- 
estimation of the cumulative incidence of HRT 
may be present. Finally, although we evaluated 
most variables known to possibly influence the 
prescription of HRT, some other factors such as 
those related to the physician were not measured. 
It may be concluded that the cumulative inci- 
dence of first HRT prescription is high, but that 
the majority of the women stop taking HRT 
within 2 years, which implies that most indications 
are rather therapeutic than preventive. When 
typical complaints are absent, women with a level 
of well-being above the median are prescribed 
HRT live times more frequently. The question 
arises whether for these women the indication is 
therapeutic, preventive or equivocal, For women 
with typical complaints the doctor’s prescription is 
primarily related to the woman’s attitude towards 
(medical) treatment of the menopause. The pro- 
cess of decision-making about starting and con- 
tinuation of HRT is complex, depending on a 
variety of determinants modified by the presence 
of the typical climacteric complaints. Insight of 
this process may contribute to a more rational 
prescription of HRT. 
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